Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of KH607 tablets in major depressive disorder
CTR20250210Phase 2Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KH607 in major depressive disorder (MDD), sponsored by Chengdu Kanghong Pharmaceutical Group. Started Jan 2025; status: completed.
02
Drugs
KH607
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20250210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250210.